As Kukje and Korea United Pharmaceutical newly entered the anti-thrombotic Ticagrelor market, it was reorganized into a competitive system for nine companies. Although the original Brilinta's material patent expired in November last year, only six pharmaceutical companies' products entered the market due to high manufacturing costs and lack of marketability. And although generics for exclusivity ended last August, no news of generics' benefit was heard that month. According to the industry on the 6th, Kukjel has obtained benefits for Ticagrelor since September and Korea United Pharmaceutical from this month.
Kukje is competing in the market with Brilor and Korea United Pharmaceutical with Tiglor. Competition, w